Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
21.72
+0.77 (3.68%)
At close: Jul 25, 2025, 4:00 PM
21.71
-0.01 (-0.05%)
After-hours: Jul 25, 2025, 7:44 PM EDT

Company Description

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies.

The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.

Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.
Beam Therapeutics logo
CountryUnited States
Founded2017
IPO DateFeb 6, 2020
IndustryBiotechnology
SectorHealthcare
Employees483
CEOJohn Evans

Contact Details

Address:
238 Main Street
Cambridge, Massachusetts 02142
United States
Phone857 327 8775
Websitebeamtx.com

Stock Details

Ticker SymbolBEAM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0000789073
CUSIP Number07373V105
ISIN NumberUS07373V1052
Employer ID13-3295276
SIC Code2080

Key Executives

NamePosition
John M. Evans M.B.A.Chief Executive Officer and Director
Dr. Giuseppe Ciaramella Ph.D.President
Sravan Kumar EmanyChief Financial Officer
Dr. Christine P. Bellon J.D., Ph.D.Senior Vice President, Chief Legal Officer and Corporate Secretary
Dr. Amy Simon M.D.Chief Medical Officer
Dr. Feng Zhang Ph.D.Co-Founder
Dr. David R. Liu Ph.D.Co-Founder
Dr. J. Keith Joung M.D., Ph.D.Co-Founder
Dr. Manmohan Singh Ph.D.Chief Technology Officer
Dr. Gopi Shanker Ph.D.Chief Scientific Officer

Latest SEC Filings

DateTypeTitle
May 12, 2014NO ACTFiling
May 12, 2014NO ACTFiling
May 12, 2014NO ACTFiling
May 12, 2014NO ACTFiling
May 12, 201415-12BSecurities registration termination
May 12, 201415-12BSecurities registration termination
May 2, 201425Filing
Apr 30, 2014S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 30, 2014S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Apr 30, 2014S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments